IBB

Innovative ETFs Channel

Biogen Tanks, Drags Down Biotechnology Sector ETFs

By Max ChenMarch 21, 2019

Innovative ETFs Channel

Healthcare, Biotech ETFs XLV and XBI Slide on FDA’s Uncertain Outlook

By Max ChenMarch 6, 2019

Equity ETF Channel

Biotech ETFs Could See More Inflows

By Tom LydonFebruary 13, 2019

Core ETF Channel

Healthcare ETFs Slip After Abbot Lab’s Revenue Miss, Weak Outlook

By Max ChenJanuary 23, 2019

Core ETF Channel

Traders Suggest Treading Carefully With Biotech ETFs

By Brenton GarenJanuary 15, 2019

Equity ETFs

Biotech ETFs Rip Higher to Start 2019

By Brenton GarenJanuary 14, 2019

Equity ETFs

Biotech ETFs Surge After Eli Lilly Buys Out Loxo Oncology

By Max ChenJanuary 7, 2019

Equity ETFs

Biotech ETFs Pop as Bristol-Myers Squibb Set to Acquire Celgene

By Max ChenJanuary 3, 2019

Equity ETFs

Pharmaceutical ETFs Could Maintain Their Momentum

By Max ChenSeptember 6, 2018

Equity ETFs

7 Healthcare ETFs Among Best Performing Defensive Picks This Year

By Max ChenAugust 22, 2018

Equity ETFs

Biotech ETFs Rally as Illumina Tops Q2 Expectations

By Max ChenJuly 31, 2018

Equity ETFs

Biotech ETFs Climb on Biogen’s Promising Clinical Trial

By Max ChenJuly 6, 2018

Investing

The Devil Is in the Details With This Market

By Iris.xyzMay 26, 2018

Equity ETFs

Will “Right to Try” Bill Boost Biotech ETFs?

By Tom LydonMay 24, 2018

Equity ETFs

6 Top Healthcare ETFs Rally as Trump Vows End to ‘Global Freeloading’

By Max ChenMay 11, 2018

Equity ETFs

Healthcare ETFs Lag Markets as Celgene Drags

By Max ChenApril 30, 2018

Equity ETFs

Big Biotech ETF Can Bounce Back

By Tom LydonApril 18, 2018

Equity ETFs

Alkermes FDA Refusal: Biotech ETFs Dragged Down

By Max ChenApril 2, 2018